Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:15:42.582Z.
Calculation as of: 2026-10-06T14:15:42.582Z.
Quote observation: 2026-10-06T14:15:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9a6fb48ec682e3cf9a2a3de0b7f1962f0667ac92b413acd908fc1cfb112ec24a
PE RATIO
N/A
Market Cap
$56.29M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apollomics, Inc. (APLM) | $53.17M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $54.14M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $56.29M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $55.97M | N/A | N/A | N/A | N/A |
| Spectral AI, Inc. (MDAI)vs › | $56.65M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $53.01M | N/A | N/A | N/A | N/A |
| Microbot Medical Inc. (MBOT)vs › | $52.41M | N/A | 6.87 | 6.87 | 6.87 |
| INmune Bio, Inc. (INMB)vs › | $51.31M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.31M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.06M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$24.21
Forward EPS (Est.)
$-122.00
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
